drugset / Trial / NCT01179828

Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)

NCT01179828

RandomizedCrossoverTriple-blindBasic science

Summary

Drug therapy in patients with chronic low back pain is a major challenge for physicians. One of the problems is the lacking knowledge in prediction of drug efficacy in a chosen patient. Usually one of the classes of pain medication is given to patients with a similar clinical picture, although different pain mechanisms may be responsible for this clinical picture. Another reason for variable drug efficacy are genetic polymorphisms, this may be the reason why an unique drug produces different responses (from a lacking analgesic effect up to excessive effect or side-effects. Quantitative sensory testing is a method that documents alterations in the pain perception system. Linking genetic polymorphisms to quantitative sensory testing may give us a tool for anticipation of drug efficacy.

Timeline

Start
2010-07
Primary completion
2015-04
Completion
2015-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clobazam Small molecule 20 mg Oral
Comparator Imipramine Small molecule 75 mg Oral
Comparator Oxycodone Other / unclassified 15 mg Oral
Comparator Tolterodine Small molecule 1 mg Oral

Indications

No indication recorded.